Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) EBITDA (2016 - 2025)

Historic EBITDA for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$66.6 million.

  • Celldex Therapeutics' EBITDA fell 7252.74% to -$66.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$226.1 million, marking a year-over-year decrease of 4978.07%. This contributed to the annual value of -$157.9 million for FY2024, which is 1325.58% down from last year.
  • According to the latest figures from Q3 2025, Celldex Therapeutics' EBITDA is -$66.6 million, which was down 7252.74% from -$56.8 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' EBITDA ranged from a high of -$13.4 million in Q2 2021 and a low of -$66.6 million during Q3 2025
  • In the last 5 years, Celldex Therapeutics' EBITDA had a median value of -$33.9 million in 2024 and averaged -$34.7 million.
  • As far as peak fluctuations go, Celldex Therapeutics' EBITDA crashed by 17328.7% in 2022, and later surged by 1636.88% in 2023.
  • Celldex Therapeutics' EBITDA (Quarter) stood at -$20.8 million in 2021, then decreased by 20.73% to -$25.1 million in 2022, then tumbled by 67.76% to -$42.1 million in 2023, then decreased by 16.46% to -$49.1 million in 2024, then plummeted by 35.77% to -$66.6 million in 2025.
  • Its last three reported values are -$66.6 million in Q3 2025, -$56.8 million for Q2 2025, and -$53.5 million during Q1 2025.